Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).
Saved in:
| Title: | Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study). |
|---|---|
| Authors: | Fujihara K; Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Fukushima, Japan; Multiple Sclerosis & Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Koriyama, Japan., Isobe N; Department of Neurology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan., Miyamoto K; Department of Neurology, Wakayama Medical University, Wakayama, Japan., Niino M; Department of Clinical Research, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan., Nakahara J; Department of Neurology, Keio University School of Medicine, Tokyo, Japan., Hattori S; Department of Biomedical Statistics, Graduate School of Medicine and Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Osaka, Japan., Tanaka M; Kyoto MS Center, Kyoto Min-Iren Chuo Hospital, Kyoto, Japan., Tahara M; Clinical Research Center and Department of Neurology, National Hospital Organization Utano National Hospital, Kyoto, Japan., Suzumura A; Department of Neurology, Kaikoukai Josai Hospital, Nagoya, Japan., Sakurai K; Department of Neurology, St. Marianna University School of Medicine, Kawasaki, Japan., Yoshikura N; Department of Neurology, Gifu University Graduate School of Medicine, Gifu, Japan., Shiomi K; Division of Respirology, Rheumatology, Infectious Diseases and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan., Ochi H; Department of Intractable Disease and Aging Science, Ehime University Graduate School of Medicine, Toon, Ehime, Japan., Nagata E; Department of Neurology, Tokai University School of Medicine, Isehara, Japan., Deguchi K; Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan., Tomizawa Y; Department of Neurology, Faculty of Medicine, Juntendo University, Tokyo, Japan., Yamashita K; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Nagatsuka T; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Adachi H; Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Nakashima I; Division of Neurology, Tohoku Medical and Pharmaceutical University, Sendai, Japan. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2026 Mar; Vol. 32 (3), pp. 302-314. Date of Electronic Publication: 2026 Feb 24. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
